Western blot analysis of extracts from HeLa cells, untreated (-) or treated with Mitomycin C (2 μg/mL, 24 hr; +), using FANCD2 (D5L5X) Rabbit mAb #16323 (upper) or α-Actinin (D6F6) XP® Rabbit mAb #6487 (lower). DNA damage caused by Mitomycin C induces monoubiquitination of FANCD2, altering its electrophoretic mobility and increasing its apparent molecular weight (5).
Chemical structure of Mitomycin C.
Mitomycin C is supplied as a lyophilized powder. For a 15 mM stock, reconstitute 5 mg of powder in 997 μl of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
|Molecular Weight||334.3 g/mol|
|Solubility||Soluble in DMSO at 15 mg/ml or water at 1 mg/ml with slight warming.|
Mitomycin C, also known as MMC, is an antitumor antibiotic isolated from Streptomyces caespitosus (1). When activated, this alkylating agent crosslinks double stranded DNA resulting in DNA damage (2). Mitomycin C has been found to have lethal effects on HeLa cells during the G1 phase of the cell cycle (3). DNA damage caused by Mitomycin C can lead to increased levels of p53 that can result in cell cycle arrest or apoptosis (4).